Scientists are sounding the alarm about a significant and often overlooked threat: fungal infections and the rising antifungal resistance that is contributing to a “silent pandemic.” While antibiotic resistance has garnered much attention, experts highlight that fungal pathogens are rapidly evolving and adapting beyond the reach of current treatments, necessitating urgent action.
According to Dr. Norman van Rhijn, a molecular biologist at the University of Manchester, fungal infections are increasingly becoming a global health crisis that is being sidelined in discussions on antimicrobial resistance. As the world prepares for a United Nations meeting on this issue, researchers emphasize the importance of including fungal infections in the conversation, which also encompasses resistant bacteria, viruses, and parasites.
Recent findings published in The Lancet reveal that fungal infections impact approximately 6.5 million people annually, resulting in around 3.8 million deaths. The disproportionate focus on bacterial pathogens has led to a lack of recognition and research on fungi, which are complex organisms that share structural similarities with human cells, complicating treatment development.
The World Health Organization (WHO) has recognized the severity of this issue, releasing the Fungal Priority Pathogen List in 2022, which systematically identifies the most dangerous fungal pathogens. Among these are Aspergillus fumigatus, which primarily affects the respiratory system; Candida albicans, a naturally occurring fungus that can cause severe infections when overproduced; Nakaseomyces glabratus, which can infect the urogenital tract and bloodstream; and Trichophyton indotinaeae, a newly identified species responsible for widespread skin infections.
Those at highest risk for life-threatening fungal infections include older adults and individuals with compromised immune systems. The complexity of fungal biology makes it challenging and costly to develop effective treatments that target these pathogens without harming human cells. Thus, experts urge governments, researchers, and pharmaceutical companies to expand their focus beyond bacteria and prioritize fungal research to prevent further escalation of this silent epidemic.
